Sonidegib free base

Sonidegib free base 

To Order Contact us: lieven@wlsolutions.be

R406(free base)

E1KS1533 2mg
EUR 625.2

R406 (free base)

HY-11108 10mM/1mL
EUR 277.2

YM158 (free base)

HY-U00355 1mg
EUR 2770.8

MCC950 (Free base)

B1031-1 each
EUR 183.6

MCC950 (Free base)

B1031-5 each
EUR 548.4

ITI214 (free base)

HY-12501 100mg
EUR 3531.6

PLX5622 (free base)

B2965-25 25 mg
EUR 903.6

PLX5622 (free base)

B2965-5 5 mg
EUR 272.4

AZD4547, Free Base

ADC-P-063 unit Ask for price

AZD8055, Free Base

ADC-P-064 unit Ask for price

AZD3839 (free base)

HY-13438 50mg
EUR 1216.8

Apatinib (Free base)

B1613-25 each
EUR 496.8

Apatinib (Free base)

B1613-5 each
EUR 170.4

Imatinib, Free base

2141-100 each
EUR 176.4

Imatinib, Free base

2141-1000 each
EUR 502.8

FR167344 free base

HY-100301 1mg
EUR 3164.4

FR183998 free base

HY-100302 1mg
EUR 1352.4

FR194738 free base

HY-100303 1mg
EUR 2388

Xylazine (free base)

Q-1445.0025 25.0g
EUR 385.2
Description: Sum Formula: C12H16N2S; CAS# [7361-61-7]

Lapatinib, Free base

2138-100 each
EUR 464.4

Lapatinib, Free base

2138-25 each
EUR 229.2

Erlotinib, Free Base

2048-100 each
EUR 189.6

Erlotinib, Free Base

2048-1000 each
EUR 464.4

Sunitinib, Free base

2097-100 each
EUR 229.2

Sunitinib, Free base

2097-1000 each
EUR 601.2

Sunitinib, Free base

2097-25 each
EUR 138

Vatalanib, Free Base

2026-25 each
EUR 366

Vatalanib, Free Base

2026-5 each
EUR 151.2

LY2835219 free base

A3575-100 100 mg
EUR 686.4
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 free base

A3575-25 25 mg
EUR 309.6
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 free base

A3575-5 5 mg
EUR 170.4
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

Carubicin (Free base)

B1853-1 each
EUR 183.6

Carubicin (Free base)

B1853-5 each
EUR 548.4

Rucaparib (free base)

A8893-10 10 mg
EUR 240
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-200 200 mg
EUR 1243.2
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-5 5 mg
EUR 164.4
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-5.1 10 mM (in 1mL DMSO)
EUR 170.4
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-50 50 mg
EUR 547.2
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

RPR107393 free base

HY-100299 1mg
EUR 577.2

Vatalanib (free base)

HY-10203 5mg
EUR 142.8

Ripasudil free base

HY-15685A 10mg
EUR 489.6

AS2863619 (free base)

HY-126675 5mg
EUR 1410

Linsitinib, Free base

2294-25 each
EUR 679.2

Linsitinib, Free base

2294-5 each
EUR 222

Tipifarnib, Free base

2296-1 each
EUR 170.4

Tipifarnib, Free base

2296-5 each
EUR 496.8

Nintedanib (free base)

GW5215-100 100
EUR 274.7

Nintedanib (free base)

GW5215-25 25
EUR 117.8

Terbinafine (Free base)

B2423-250 each
EUR 248.4

Terbinafine (Free base)

B2423-50 each
EUR 144

Ruxolitinib (free base)

10-042 25 mg
EUR 418.2
Description: Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19).

Cyclopamine, Free Base

27013 10 mg
EUR 130
Description: Cyclopamine inhibits activation of the Hedgehog response pathway by binding to and inhibiting the proto-oncogene Smoothened (SMO). The effects of oncogenic mutations that either activate SMO or inactivate the tumor suppressor Patched (Ptch) can be reversed by cyclopamine treatment. Cyclopamine has also been shown to induce apoptosis in colorectal adenoma cell lines, carcinoma-derived cell lines, and skin basal cell carcinomas and is being investigated as an anti-cancer drug.

Ruxolitinib, Free base

2139-100 each Ask for price

Ruxolitinib, Free base

2139-25 each
EUR 639.6

Ruxolitinib, Free base

2139-5 each
EUR 248.4

Cyclopamine, Free Base

ADC-P-079 unit Ask for price

Ixabepilone, Free Base

ADC-P-104 unit Ask for price

Masupirdine (free base)

HY-109118 1mg
EUR 267.6

Ruxolitinib (free base)

GW2265-100 100
EUR 404.9

Ruxolitinib (free base)

GW2265-25 25
EUR 216.3

Ruxolitinib (free base)

GW2265-5 5
EUR 116.1

GSK J4 free base

B5959-10 10 mg
EUR 447.6
Description: GSK J4 free base

GSK J4 free base

B5959-50 50 mg
EUR 1437.6
Description: GSK J4 free base

DOV-216,303 (Free Base)

HY-18332C 10mM/1mL
EUR 590.4

GSK-J4 (Free base)

2762-1 each
EUR 144

GSK-J4 (Free base)

2762-5 each
EUR 314.4

AM-095 free base

A3167-10 10 mg
EUR 254.4
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-100 100 mg
EUR 964.8
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-200 200 mg
EUR 1382.4
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-5 5 mg
EUR 199.2
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-50 50 mg
EUR 686.4
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AV-412 (free base)

HY-10346A 5mg
EUR 207.6

FK-448 Free base

HY-100193 10mg
EUR 2264.4

UNC-926, free base

B2158-25 each
EUR 757.2

UNC-926, free base

B2158-5 each
EUR 235.2

KW-8232 free base

HY-100304 10mg
EUR 6021.6

APX-115 (free base)

HY-120801A 5mg
EUR 267.6

JTV-519 (free base)

HY-15293A 5mg
EUR 680.4

Z-NHNH2 (free base)

Q-1150.0025 25.0g
EUR 151.2
Description: Sum Formula: C8H10N2O2; CAS# [5331-43-1]

Z-NHNH2 (free base)

Q-1150.0100 100.0g
EUR 385.2
Description: Sum Formula: C8H10N2O2; CAS# [5331-43-1]

SGI-1776 free base

27651-1 5 mg
EUR 155
Description: SGI-1776 is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival. Through extensive biomedical characterization, SGI-1776 exhibits specificity to the three isoforms of the Pim family, including Pim-1, Pim-2, and Pim-3. Treatment with SGI-1776 induces apoptosis in CLL primary cell line.

SGI-1776 free base

27651-2 10 mg
EUR 235
Description: SGI-1776 is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival. Through extensive biomedical characterization, SGI-1776 exhibits specificity to the three isoforms of the Pim family, including Pim-1, Pim-2, and Pim-3. Treatment with SGI-1776 induces apoptosis in CLL primary cell line.

SGI-1776 free base

27651-3 50 mg
EUR 510
Description: SGI-1776 is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival. Through extensive biomedical characterization, SGI-1776 exhibits specificity to the three isoforms of the Pim family, including Pim-1, Pim-2, and Pim-3. Treatment with SGI-1776 induces apoptosis in CLL primary cell line.

SGI-1776 free base

A4192-10 10 mg
EUR 296.4
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

Sonidegib free base